

Lupin, Endoceutics focus on women's health in Canada

09 March 2021 | News

Intrarosa® is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy



Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, has announced a partnership with Endoceutics, a women's health focused innovative Canadian biotech company, to commercialise Intrarosa® in Canada.

Intrarosa® is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.

Commenting on the partnership, Dr Sofia Mumtaz, President, Lupin Pharma Canada said, "We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into women's health in Canada but will cater to satisfy the unmet medical needs."

"We are very excited to be working closely with Lupin in Canada. We believe they are the right partner to successfully bring Intrarosa to the market," commented Dennis Turpin, President and Chief Executive Officer, Endoceutics.

It is estimated that over 50 per cent of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10 per cent of these women are treated with prescription medicines.